Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,808 questions · 8,953 findings · 827 reviews · Headline outcomes only

No studies found 1,891 · 21.1%GRADE not reported 380 · 4.2%Very low 2,100 · 23.5%Low 2,449 · 27.4%Moderate 1,684 · 18.8%High 449 · 5%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Group C cognitive behavioural therapy: cognitive behavioural therapy + risperidone vs placebo or supportive treatment

Adverse effects: specific ‐ doctors' assessment of adverse effects UKU (events) Medium‐term · people in the prodromal stage of psychosis

It is very uncertain whether group C cognitive behavioural therapy: cognitive behavioural therapy… changes adverse effects: doctors' assessment of adverse effects UKU (events)… compared with supportive therapy + placebo (very low certainty).

1 finding from 1 review

Group C cognitive behavioural therapy: cognitive behavioural therapy + risperidone vs placebo or supportive treatment

Satisfaction with treatment: leaving the study early Endpoint data (events) · people in the prodromal stage of psychosis

It is very uncertain whether group C cognitive behavioural therapy: cognitive behavioural therapy… changes satisfaction with treatment: leaving the study early Endpoint data… compared with supportive therapy + placebo (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi with chemotherapy vs chemotherapy alone

Progression‐free survival · platinum‐sensitive recurrent EOC

It is very uncertain whether summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… changes progression‐free survival (PFS) compared with chemotherapy alone (very low certainty).

1 finding from 1 review

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi with chemotherapy vs chemotherapy alone

Adverse events (grade ≥ 3) · platinum‐sensitive recurrent EOC

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi… showed no clear difference in any severe adverse event (grade 3 or higher) (G3+ SevAE) compared with chemotherapy alone (low certainty).

1 finding from 1 review

Laser therapy plus other treatment vs other treatment

Scar severity ‐ 585‐nm pulsed‐dye laser (PDL) plus triamcinolone acetonide (TAC) plus 5‐Fluorouracil (5‐FU) versus TAC plus 5‐FU ‐ blinded observer assessment of good to excellent scar improvement ‐ hypertrophic and keloid scars ‐ · participants with hypertrophic and keloid scars

It is very uncertain whether laser therapy plus other treatment changes scar severity ‐ 585‐nm pulsed‐dye laser (PDL) plus triamcinolone… compared with other treatment (very low certainty).

1 finding from 1 review

Laser therapy plus other treatment vs other treatment

Scar severity ‐ 585‐nm PDL plus TAC plus 5 FU versus TAC plus 5‐FU ‐ patient self‐assessment of good to excellent scar improvement ‐ hypertrophic and keloid scars ‐ · participants with hypertrophic and keloid scars

It is very uncertain whether laser therapy plus other treatment changes scar severity ‐ 585‐nm PDL plus TAC plus 5 FU versus TAC plus 5‐FU ‐… compared with other treatment (very low certainty).

1 finding from 1 review

Laser therapy plus other treatment vs other treatment

Incidence of treatment‐related adverse effects: CO2 laser plus TAC versus cryosurgery plus TAC ‐ atrophy ‐ keloid scars ‐ · participants with hypertrophic and keloid scars

It is very uncertain whether laser therapy plus other treatment changes incidence of treatment‐related adverse effects: CO2 laser plus TAC… compared with other treatment (very low certainty).

1 finding from 1 review

Laser therapy plus other treatment vs other treatment

Incidence of treatment‐related adverse effects ‐ CO2 laser plus TAC versus cryosurgery plus TAC ‐ erythema ‐ keloid scars ‐ · participants with hypertrophic and keloid scars

It is very uncertain whether laser therapy plus other treatment changes incidence of treatment‐related adverse effects ‐ CO2 laser plus TAC… compared with other treatment (very low certainty).

1 finding from 1 review

Laser therapy plus other treatment vs other treatment

Incidence of treatment‐related adverse effects ‐ CO2 laser plus TAC versus cryosurgery plus TAC ‐ telangiectasia ‐ keloid scars ‐ · participants with hypertrophic and keloid scars

It is very uncertain whether laser therapy plus other treatment changes incidence of treatment‐related adverse effects ‐ CO2 laser plus TAC… compared with other treatment (very low certainty).

1 finding from 1 review

Laser therapy plus other treatment vs other treatment

Incidence of treatment‐related adverse effects ‐ CO2 laser plus TAC versus cryosurgery plus TAC ‐ hypopigmentation ‐ keloid scars ‐ · participants with hypertrophic and keloid scars

It is very uncertain whether laser therapy plus other treatment changes incidence of treatment‐related adverse effects ‐ CO2 laser plus TAC… compared with other treatment (very low certainty).

1 finding from 1 review

Laser therapy plus other treatment vs other treatment

Scar severity ‐ Neodymium‐doped yttrium aluminium garnet (Nd:YAG) laser plus Diprospan plus 5‐FU versus Diprospan plus 5‐FU ‐ blinded observer assessment of good to excellent scar improvement ‐ keloid scars ‐ · participants with hypertrophic and keloid scars

It is very uncertain whether laser therapy plus other treatment changes scar severity ‐ Neodymium‐doped yttrium aluminium garnet (Nd:YAG)… compared with other treatment (very low certainty).

1 finding from 1 review

Laser therapy plus other treatment vs other treatment

Scar severity: Nd:YAG laser plus Diprospan plus 5‐FU versus Diprospan plus 5‐FU ‐ patient self‐assessment of scar improvement of 50% or higher ‐ keloid scars ‐ · participants with hypertrophic and keloid scars

It is very uncertain whether laser therapy plus other treatment changes scar severity: Nd:YAG laser plus Diprospan plus 5‐FU versus… compared with other treatment (very low certainty).

1 finding from 1 review